ATE218330T1 - Verwendung von transglutaminasehemmer zur behandlung des narbegewebes - Google Patents

Verwendung von transglutaminasehemmer zur behandlung des narbegewebes

Info

Publication number
ATE218330T1
ATE218330T1 AT92906696T AT92906696T ATE218330T1 AT E218330 T1 ATE218330 T1 AT E218330T1 AT 92906696 T AT92906696 T AT 92906696T AT 92906696 T AT92906696 T AT 92906696T AT E218330 T1 ATE218330 T1 AT E218330T1
Authority
AT
Austria
Prior art keywords
pct
scar tissue
transglutamine
inhibitors
sec
Prior art date
Application number
AT92906696T
Other languages
English (en)
Inventor
Kenneth N Dolynchuk
John Michael Bowness
Original Assignee
Univ Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba filed Critical Univ Manitoba
Application granted granted Critical
Publication of ATE218330T1 publication Critical patent/ATE218330T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92906696T 1992-03-23 1992-03-23 Verwendung von transglutaminasehemmer zur behandlung des narbegewebes ATE218330T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA1992/000123 WO1993018760A1 (en) 1992-03-23 1992-03-23 Use of transglutaminase inhibitor for the treatment of scar tissue

Publications (1)

Publication Number Publication Date
ATE218330T1 true ATE218330T1 (de) 2002-06-15

Family

ID=4172922

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92906696T ATE218330T1 (de) 1992-03-23 1992-03-23 Verwendung von transglutaminasehemmer zur behandlung des narbegewebes

Country Status (10)

Country Link
US (1) US5885982A (de)
EP (1) EP0632723B1 (de)
AT (1) ATE218330T1 (de)
AU (1) AU674828B2 (de)
BR (1) BR9207109A (de)
CA (1) CA2132416C (de)
DE (1) DE69232629T2 (de)
DK (1) DK0632723T3 (de)
ES (1) ES2177527T3 (de)
WO (1) WO1993018760A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6620596A (en) * 1996-07-25 1998-02-20 Victoria University Of Manchester, The Use of transglutaminase modulators to promote wound healing
US6060471A (en) * 1998-01-21 2000-05-09 Styczynski; Peter Reduction of hair growth
JP3012923B2 (ja) * 1998-01-26 2000-02-28 新潟大学長 Ｃａｇリピート病の治療薬
AU2006203098B2 (en) * 1998-03-11 2009-10-08 Kabushiki Kaisha Soken Skin conditioner
JP4522580B2 (ja) * 1998-03-11 2010-08-11 株式会社創研 皮膚健全化剤
US20040067212A1 (en) 1998-03-11 2004-04-08 Kabushiki Kaisha Soken Skin conditioner
JP2002510618A (ja) * 1998-04-03 2002-04-09 イレンチャック，セオドア，トニー 皮膚科症状の治療へのポリアミンの使用
CA2384080C (en) * 1999-09-07 2012-03-20 Kabushiki Kaisha Soken Skin conditioner
EP1645248B8 (de) * 2000-02-04 2010-06-16 Warsaw Orthopedic, Inc. Ausdehnbares interspinales Fusionsimplantat mit schwenkbarem Blocker
US6709458B2 (en) * 2000-02-04 2004-03-23 Gary Karlin Michelson Expandable push-in arcuate interbody spinal fusion implant with tapered configuration during insertion
US6814756B1 (en) 2000-02-04 2004-11-09 Gary K. Michelson Expandable threaded arcuate interbody spinal fusion implant with lordotic configuration during insertion
US6716247B2 (en) 2000-02-04 2004-04-06 Gary K. Michelson Expandable push-in interbody spinal fusion implant
US6500205B1 (en) * 2000-04-19 2002-12-31 Gary K. Michelson Expandable threaded arcuate interbody spinal fusion implant with cylindrical configuration during insertion
US6808537B2 (en) 2000-07-07 2004-10-26 Gary Karlin Michelson Expandable implant with interlocking walls
US7118579B2 (en) * 2001-02-04 2006-10-10 Sdgi Holdings, Inc. Instrumentation for inserting an expandable interbody spinal fusion implant
US7045550B2 (en) 2001-08-07 2006-05-16 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
GB0515003D0 (en) * 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
ATE469168T1 (de) 2005-12-16 2010-06-15 Nat Cancer Ct Peptide zur transglutaminase-hemmung
CA2706630A1 (en) * 2007-11-27 2009-06-04 Kenneth Nicholis Dolynchuk Use of transglutaminase inhibitor in skin treatment
US20100316764A1 (en) * 2009-06-10 2010-12-16 Engrain, LLC Flour supplement compositions and methods for preparing wheat flour
US20190298688A1 (en) * 2016-11-21 2019-10-03 Vivier Canada Inc. Putrescine slow-release topical formulations
WO2018126321A1 (en) * 2017-01-06 2018-07-12 Vivier Canada Inc. Putrescine topical barrier formulation
CA3099843A1 (en) * 2018-06-08 2019-12-12 Vivier Canada Inc. Sterile topical saline putrescine formulation and uses thereof
WO2020163942A1 (en) 2019-02-12 2020-08-20 Vivier Canada Inc. High concentration vitamin c topical compositions and method of making same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588110A (en) * 1978-05-31 1981-04-15 Geistlich Soehne Ag Pharmaceutical compositions for the treatment of scars
US4618490A (en) * 1980-06-06 1986-10-21 Marco Peter T De Method of treatment of animal and human tissues damaged by burns and frank visible gangrene
US4444787A (en) * 1981-07-06 1984-04-24 Board Of Regents, University Of Texas Ophthalmic topical use of collagen cross-linking inhibitors
US4428939A (en) * 1981-10-16 1984-01-31 Prockop Darwin J Collagen inhibiting compositions and processes for manufacturing and using same
US4507321A (en) * 1982-02-17 1985-03-26 The Research Foundation Of State University Of New York Epithelial cell growth regulating composition containing polyamines and a method of using same
US4485088A (en) * 1982-03-26 1984-11-27 Bio-Products, Inc. Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs
US4929630A (en) * 1986-03-14 1990-05-29 Syntex (U.S.A.) Inc. Transglutaminase inhibitors
US4694021A (en) * 1986-05-05 1987-09-15 Schweiger Raymond H Method for topical treatment of scar tissue
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
US4970297A (en) * 1987-03-13 1990-11-13 Syntex (U.S.A.) Inc. Transglutaminase inhibitors
US5132119A (en) * 1989-07-31 1992-07-21 Massachusetts Institute Of Technology Treatment of hypertrophic wound healing disorders with calcium channel blockers
US4968713A (en) * 1989-07-31 1990-11-06 Merck & Co., Inc. Certain imidazole compounds as transglutaminase inhibitors
US4997854A (en) * 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5124358A (en) * 1990-01-16 1992-06-23 The Board Of Reagents The University Of Texas System Effect of transglutaminase inhibition on microfilariae development and macrofilariae viability
US5324508A (en) * 1990-06-11 1994-06-28 The Curators Of The University Of Missouri Method for decreasing the formation of scar tissue using a purified mammalian monokine product
US5120322A (en) * 1990-06-13 1992-06-09 Lathrotec, Inc. Method and apparatus for treatment of fibrotic lesions
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma

Also Published As

Publication number Publication date
WO1993018760A1 (en) 1993-09-30
AU674828B2 (en) 1997-01-16
US5885982A (en) 1999-03-23
EP0632723A1 (de) 1995-01-11
CA2132416A1 (en) 1993-09-30
BR9207109A (pt) 1995-12-12
DE69232629T2 (de) 2003-01-30
DK0632723T3 (da) 2002-09-09
DE69232629D1 (de) 2002-07-11
EP0632723B1 (de) 2002-06-05
CA2132416C (en) 2001-03-06
ES2177527T3 (es) 2002-12-16
AU1544892A (en) 1993-10-21

Similar Documents

Publication Publication Date Title
ATE218330T1 (de) Verwendung von transglutaminasehemmer zur behandlung des narbegewebes
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE292462T1 (de) Behandlung von asthma anhand von mek-inhibitoren
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE233558T1 (de) Verwendung von strontiumsälze zur behandlung von arthrose
DE69616375D1 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
ATE259640T1 (de) Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE69525847D1 (de) Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
DE69629578D1 (de) Verwendung von wenigstens einem no-synthase hemmer zur behandlung empfindlicher haut
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
ATE229331T1 (de) Inhibitoren von metazoan-parasit-proteasen
ATE344668T1 (de) Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
DE69519582D1 (de) Kontrolle des haarwuchses
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
DE60315238D1 (de) Verwendung eines Assoziates aus synergistischen Kalziumkanalblocker-Agentien zur Vermeidung oder Behandlung von Falten und feinen Linien
ATE239468T1 (de) Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen
DE69716434D1 (de) Verwendung von lysin zur behandlung des haarausfalls
SE9403831D0 (sv) A storage stable water solution for infusion I
DE69330465D1 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4-aza-5 alpha-androst-1-en-3-one
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
DE69724112D1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung
ATE225660T1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee